+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibiotics Market by Drug Class, Type, Spectrum, Route of Administration, Application, Distribution Channel - Global Forecast 2026-2032- Product Image
Antibiotics Market by Drug Class, Type, Spectrum, Route of Administration, Application, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Antibiotics Market by Drug Class, Type, Spectrum, Route of Administration, Application, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 191 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5264378
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antibiotics Market is projected to reach USD 52.25 Billion in 2026. It is expected to continue growing at a CAGR of 7.14%, reaching USD 79.38 Billion by 2032.

The antibiotics market remains a critical pillar of modern medicine, supporting the treatment of bacterial infections across hospitals, outpatient care, surgery, oncology, transplantation, maternal health, and intensive care. Demand is shaped by the persistent infectious disease burden, aging populations, increased surgical volumes, and the continued need for effective antibacterial therapy in both community-acquired and healthcare-associated infections.

At the same time, antimicrobial resistance is redefining industry priorities. The World Health Organization identifies antimicrobial resistance as one of the top global public health threats, and the 2019 global burden analysis estimated 1.27 million deaths directly attributable to bacterial AMR and 4.95 million deaths associated with it. This creates a dual market reality: antibiotics remain indispensable, but sustainable progress depends on innovation, stewardship, diagnostics, resilient supply chains, and policy-backed incentives that preserve clinical effectiveness.

Transformative Shifts in the Antibiotics Landscape

The antibiotics landscape is shifting from volume-led prescribing toward evidence-based, resistance-aware treatment models. Health systems are strengthening antimicrobial stewardship programs, increasing the use of culture-based testing and rapid diagnostics, and aligning procurement with essential medicines frameworks such as the WHO AWaRe classification, which encourages broader use of Access antibiotics while protecting Watch and Reserve agents.

Commercial models are also changing. Traditional antibiotic revenues are constrained by short treatment durations, generic competition, and stewardship-driven conservation, while development costs remain high. As a result, industry leaders are prioritizing differentiated mechanisms of action, narrow-spectrum agents, beta-lactamase inhibitor combinations, pathogen-specific therapies, and subscription-style reimbursement models that reward availability and clinical value rather than sales volume.

Cumulative Impact of Artificial Intelligence on Antibiotics

Artificial intelligence is beginning to influence antibiotic discovery, optimization, surveillance, and clinical decision support. Peer-reviewed studies have demonstrated AI-assisted identification of novel antibacterial candidates such as halicin and abaucin, illustrating how machine learning can screen chemical space at speeds not feasible through conventional laboratory workflows alone.

The cumulative impact of AI is most valuable when integrated with high-quality microbiology data, electronic health records, genomics, and stewardship protocols. AI can support earlier resistance detection, predict treatment failure risk, optimize empiric therapy, and strengthen pharmacovigilance. However, successful deployment requires validated datasets, clinical oversight, transparent algorithms, and regulatory alignment to ensure that automation improves antibiotic use without accelerating inappropriate prescribing.

Key Regional Insights for the Antibiotics Market

Asia-Pacific is a major demand center for antibiotics due to large populations, high infectious disease burden, expanding healthcare access, and significant generic manufacturing capacity, with China, India, Japan, South Korea, and Australia shaping different parts of the value chain. North America is driven by advanced hospital systems, infectious disease surveillance, stewardship mandates, and adoption of novel agents for resistant Gram-negative infections, while the United States remains influential in regulatory pathways, hospital antibiotic use standards, and commercialization models.

Latin America is marked by broad antibiotic access needs, uneven stewardship implementation, and rising investment in hospital infection control, with Brazil and Mexico serving as important regional markets. Europe is characterized by mature reimbursement systems, coordinated AMR policy, and stronger restrictions on inappropriate antibiotic use, with the European Union emphasizing surveillance, One Health action, and supply security. The Middle East is expanding specialist care, hospital infrastructure, and centralized procurement, particularly across GCC countries, while Africa faces the dual challenge of improving access to essential antibiotics and reducing misuse, substandard medicines, and treatment gaps.

Key Group Insights Across Global Antibiotics Markets

ASEAN represents a fast-evolving antibiotics environment where rising healthcare utilization, infectious disease burden, and expanding private care are increasing demand, while governments intensify AMR action plans and stewardship education. GCC countries are investing in advanced hospitals, infection prevention, laboratory modernization, and procurement systems, creating opportunities for high-quality antibacterial products and diagnostics that support responsible prescribing.

The European Union remains a global reference point for coordinated antimicrobial resistance surveillance, regulatory oversight, and One Health policy. BRICS countries combine large patient populations, manufacturing strength, and growing research and development ambitions, making them central to both access and innovation discussions. G7 markets drive global standards in antibiotic stewardship, reimbursement reform, and advanced clinical research, while NATO countries increasingly view antimicrobial resistance and medicine supply resilience as health security priorities linked to preparedness, military medicine, and defense readiness.

Key Country Insights in the Antibiotics Market

The United States combines high-value innovation, CDC-led resistance monitoring, and hospital stewardship requirements, with demand concentrated in severe infections, resistant pathogens, and outpatient respiratory, urinary, and skin infections. Canada emphasizes stewardship and formulary discipline, while Mexico and Brazil balance broad access needs with growing regulatory attention to prescription control, antimicrobial use monitoring, and hospital infection prevention.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are mature antibiotic markets shaped by national AMR strategies, reimbursement scrutiny, infection prevention standards, and demand for novel agents targeting resistant bacteria. Russia remains an important market with domestic production considerations and significant infectious disease treatment needs. In Asia-Pacific, China and India are central due to population scale, generics manufacturing, and policy efforts to improve antibiotic governance; Japan, Australia, and South Korea are advanced markets with strong stewardship, high clinical standards, robust diagnostics adoption, and interest in innovative therapies for resistant infections.

Actionable Recommendations for Antibiotics Industry Leaders

Industry leaders should prioritize antibiotic portfolios that address WHO and national priority pathogens, especially resistant Gram-negative bacteria, while differentiating products through clinical evidence, pathogen specificity, safety, and compatibility with stewardship requirements. Organizations should invest in lifecycle management, combination strategies, pediatric formulations, and reliable supply of essential antibiotics to strengthen both access and resilience.

Vendors should also align commercial strategies with diagnostics, surveillance data, and value-based reimbursement. Partnerships with hospitals, public health agencies, biotechnology innovators, and diagnostic developers can accelerate adoption while supporting responsible use. Preparing for subscription-style payment models, AMR pull incentives, and procurement criteria tied to supply continuity will be essential for long-term competitiveness.

Research Methodology for Antibiotics Market Insights

This executive summary is developed using a secondary research-led methodology that synthesizes verified public health, regulatory, clinical, and industry sources. Core reference points include data and guidance from the World Health Organization, Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, national AMR action plans, peer-reviewed literature, and publicly available regulatory information.

The analysis emphasizes evidence-backed market drivers, resistance trends, regional healthcare dynamics, stewardship policies, and technology adoption patterns. Insights are validated through triangulation across epidemiology, prescribing behavior, innovation pipeline trends, healthcare infrastructure, and policy developments to provide a balanced view of the antibiotics market without relying on unsupported estimates, market sizing, or forecasting.

Conclusion: Future Direction for the Antibiotics Market

The antibiotics market is entering a decisive phase in which clinical necessity, antimicrobial resistance, policy reform, and technological innovation are converging. Antibiotics will remain essential to healthcare systems, but future market success will depend on delivering effective therapies while preserving their utility through stewardship and evidence-based prescribing.

Organizations that combine scientific differentiation, responsible commercialization, AI-enabled discovery, rapid diagnostics, and resilient manufacturing will be best positioned to lead. As AMR continues to shape global health priorities, the antibiotics industry must balance access, innovation, and conservation to sustain long-term value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Antibiotics Market, by Drug Class
7.1. Beta-Lactams
7.1.1. Penicillins
7.1.1.1. Natural Penicillins
7.1.1.2. Aminopenicillins
7.1.1.3. Penicillinase-Resistant Penicillins
7.1.1.4. Antipseudomonal Penicillins
7.1.2. Cephalosporins
7.1.2.1. First Generation
7.1.2.2. Second Generation
7.1.2.3. Third Generation
7.1.2.4. Fourth Generation
7.1.2.5. Fifth Generation
7.1.3. Carbapenems
7.1.4. Monobactams
7.2. Macrolides
7.3. Fluoroquinolones
7.4. Tetracyclines
7.5. Aminoglycosides
7.6. Glycopeptides And Lipoglycopeptides
7.7. Sulfonamides And Trimethoprim
7.8. Oxazolidinones
7.9. Nitroimidazoles
8. Antibiotics Market, by Type
8.1. Natural
8.2. Synthetic
9. Antibiotics Market, by Spectrum
9.1. Broad Spectrum
9.2. Narrow Spectrum
10. Antibiotics Market, by Route Of Administration
10.1. Oral
10.2. Parenteral
10.2.1. Intravenous
10.2.2. Intramuscular
10.3. Topical
10.3.1. Dermatological
10.3.2. Ophthalmic
10.4. Inhalation
11. Antibiotics Market, by Application
11.1. Human
11.2. Veterinary
12. Antibiotics Market, by Distribution Channel
12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy
13. Asia-Pacific Antibiotics Market
14. Europe Antibiotics Market
15. North America Antibiotics Market
16. Latin America Antibiotics Market
17. Africa Antibiotics Market
18. Middle East Antibiotics Market
19. NATO Antibiotics Market
20. G7 Antibiotics Market
21. BRICS Antibiotics Market
22. European Union Antibiotics Market
23. ASEAN Antibiotics Market
24. GCC Antibiotics Market
25. China Antibiotics Market
26. United States Antibiotics Market
27. Japan Antibiotics Market
28. India Antibiotics Market
29. Germany Antibiotics Market
30. United Kingdom Antibiotics Market
31. Australia Antibiotics Market
32. France Antibiotics Market
33. South Korea Antibiotics Market
34. Italy Antibiotics Market
35. Canada Antibiotics Market
36. Russia Antibiotics Market
37. Brazil Antibiotics Market
38. Mexico Antibiotics Market
39. Spain Antibiotics Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Abbott Laboratories
41.2. AbbVie Inc
41.3. Astellas Pharma Inc
41.4. Astra Zeneca plc
41.5. Aurobindo Pharma Ltd
41.6. Bayer AG
41.7. Bristol Myers Squibb Company
41.8. Cipla Ltd
41.9. Dr Reddy’s Laboratories Ltd
41.10. Eli Lilly and Company
41.11. Glaxo Smith Kline plc
41.12. Johnson & Johnson Services Inc
41.13. Lupin Limited
41.14. Merck & Co Inc
41.15. Novartis AG
41.16. Pfizer Inc
41.17. Sanofi S A
41.18. Sun Pharmaceutical Industries Ltd
41.19. Teva Pharmaceutical Industries Ltd
41.20. Zydus Lifesciences Ltd
List of Figures
FIGURE 1. GLOBAL ANTIBIOTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTIBIOTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTIBIOTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTIBIOTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTIBIOTICS MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTIBIOTICS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. NATO ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. NATO ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. G7 ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. G7 ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. ASEAN ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. ASEAN ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. GCC ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. GCC ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. CHINA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. UNITED STATES ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. JAPAN ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. INDIA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. GERMANY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. AUSTRALIA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. FRANCE ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. SOUTH KOREA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. ITALY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CANADA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. RUSSIA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. BRAZIL ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. MEXICO ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTIBIOTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BETA-LACTAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BETA-LACTAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BETA-LACTAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NATURAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NATURAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NATURAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL AMINOPENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL AMINOPENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL AMINOPENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PENICILLINASE-RESISTANT PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PENICILLINASE-RESISTANT PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PENICILLINASE-RESISTANT PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTIPSEUDOMONAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTIPSEUDOMONAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIPSEUDOMONAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL FIRST GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL FIRST GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL FIRST GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SECOND GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SECOND GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SECOND GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL THIRD GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL THIRD GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL THIRD GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL FOURTH GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL FOURTH GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL FOURTH GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL FIFTH GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL FIFTH GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL FIFTH GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CARBAPENEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CARBAPENEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CARBAPENEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MONOBACTAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MONOBACTAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL MONOBACTAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL MACROLIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MACROLIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MACROLIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL TETRACYCLINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL TETRACYCLINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL TETRACYCLINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL SULFONAMIDES AND TRIMETHOPRIM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL SULFONAMIDES AND TRIMETHOPRIM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SULFONAMIDES AND TRIMETHOPRIM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL OXAZOLIDINONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL OXAZOLIDINONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL OXAZOLIDINONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NITROIMIDAZOLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NITROIMIDAZOLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NITROIMIDAZOLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NATURAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NATURAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NATURAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL SYNTHETIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL SYNTHETIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL SYNTHETIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL BROAD SPECTRUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL BROAD SPECTRUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL BROAD SPECTRUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NARROW SPECTRUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL NARROW SPECTRUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL NARROW SPECTRUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL DERMATOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL DERMATOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL DERMATOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL OPHTHALMIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL OPHTHALMIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL OPHTHALMIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL HUMAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL HUMAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL HUMAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL VETERINARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL VETERINARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL VETERINARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. EUROPE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. EUROPE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 145. EUROPE ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 146. EUROPE ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 147. EUROPE ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 149. EUROPE ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 150. EUROPE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. EUROPE ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 152. EUROPE ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 153. EUROPE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 154. EUROPE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. AFRICA ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 180. AFRICA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 181. AFRICA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 182. AFRICA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 183. AFRICA ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 184. AFRICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 185. AFRICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 186. AFRICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 187. AFRICA ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 188. AFRICA ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 189. AFRICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 190. AFRICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 192. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 193. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 196. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. NATO ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 204. NATO ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 205. NATO ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 206. NATO ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 207. NATO ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 208. NATO ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 209. NATO ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 210. NATO ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 211. NATO ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 212. NATO ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 213. NATO ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 214. NATO ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 215. G7 ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 216. G7 ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 217. G7 ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 218. G7 ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 219. G7 ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 220. G7 ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 221. G7 ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 222. G7 ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 223. G7 ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 224. G7 ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 225. G7 ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 226. G7 ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 227. BRICS ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 228. BRICS ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 229. BRICS ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 230. BRICS ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 231. BRICS ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 232. BRICS ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 233. BRICS ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 234. BRICS ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 235. BRICS ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 236. BRICS ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 237. BRICS ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 238. BRICS ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 251. ASEAN ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 252. ASEAN ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 253. ASEAN ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 254. ASEAN ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 255. ASEAN ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 256. ASEAN ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 257. ASEAN ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 258. ASEAN ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 259. ASEAN ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 260. ASEAN ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 261. ASEAN ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 262. ASEAN ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 263. GCC ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 264. GCC ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 265. GCC ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 266. GCC ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 267. GCC ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 268. GCC ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 269. GCC ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 270. GCC ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 271. GCC ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 272. GCC ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 273. GCC ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 274. GCC ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 275. CHINA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 276. CHINA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 277. CHINA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 278. CHINA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 279. CHINA ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 280. CHINA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 281. CHINA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 282. CHINA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 283. CHINA ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 284. CHINA ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 285. CHINA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 286. CHINA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 287. UNITED STATES ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 288. UNITED STATES ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 289. UNITED STATES ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 290. UNITED STATES ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 291. UNITED STATES ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 292. UNITED STATES ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 293. UNITED STATES ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 294. UNITED STATES ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 295. UNITED STATES ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 296. UNITED STATES ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 297. UNITED STATES ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 298. UNITED STATES ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 299. JAPAN ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 300. JAPAN ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 301. JAPAN ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 302. JAPAN ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 303. JAPAN ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 304. JAPAN ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 305. JAPAN ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 306. JAPAN ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 307. JAPAN ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 308. JAPAN ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 309. JAPAN ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 310. JAPAN ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 311. INDIA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 312. INDIA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 313. INDIA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 314. INDIA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 315. INDIA ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 316. INDIA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 317. INDIA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 318. INDIA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 319. INDIA ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 320. INDIA ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 321. INDIA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 322. INDIA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 323. GERMANY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 324. GERMANY ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 325. GERMANY ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 326. GERMANY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 327. GERMANY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 328. GERMANY ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 329. GERMANY ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 330. GERMANY ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 331. GERMANY ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 332. GERMANY ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 333. GERMANY ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 334. GERMANY ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 335. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 336. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 337. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 338. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 339. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 340. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 341. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 342. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 343. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 344. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 345. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 346. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 347. AUSTRALIA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 348. AUSTRALIA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 349. AUSTRALIA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 350. AUSTRALIA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 351. AUSTRALIA ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 352. AUSTRALIA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 353. AUSTRALIA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 354. AUSTRALIA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 355. AUSTRALIA ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 356. AUSTRALIA ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 357. AUSTRALIA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 358. AUSTRALIA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 359. FRANCE ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 360. FRANCE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 361. FRANCE ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 362. FRANCE ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 363. FRANCE ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 364. FRANCE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 365. FRANCE ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 366. FRANCE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 367. FRANCE ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 368. FRANCE ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 369. FRANCE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 370. FRANCE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 371. SOUTH KOREA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 372. SOUTH KOREA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 373. SOUTH KOREA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 374. SOUTH KOREA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 375. SOUTH KOREA ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 376. SOUTH KOREA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 377. SOUTH KOREA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 378. SOUTH KOREA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 379. SOUTH KOREA ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 380. SOUTH KOREA ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 381. SOUTH KOREA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 382. SOUTH KOREA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 383. ITALY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 384. ITALY ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 385. ITALY ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 386. ITALY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 387. ITALY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 388. ITALY ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 389. ITALY ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
TABLE 390. ITALY ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 391. ITALY ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 392. ITALY ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 393. ITALY ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 3

Companies Mentioned

The companies featured in this Antibiotics market report include:
  • Abbott Laboratories
  • AbbVie Inc
  • Astellas Pharma Inc
  • Astra Zeneca plc
  • Aurobindo Pharma Ltd
  • Bayer AG
  • Bristol Myers Squibb Company
  • Cipla Ltd
  • Dr Reddy’s Laboratories Ltd
  • Eli Lilly and Company
  • Glaxo Smith Kline plc
  • Johnson & Johnson Services Inc
  • Lupin Limited
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Sanofi S A
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Zydus Lifesciences Ltd

Table Information

Report AttributeDetails
No. of Pages191
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 52.25 Billion
Forecasted Market Value ( USD ) by 2032 $ 79.38 Billion
Compound Annual Growth Rate7.1%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Antibacterial Drugs - Global Strategic Business Report - Product Image

Antibacterial Drugs - Global Strategic Business Report

  • Report
  • 244 Pages
  • Global
From
EU - Antibiotics - Market Analysis, Forecast, Size, Trends and Insights - Product Image

EU - Antibiotics - Market Analysis, Forecast, Size, Trends and Insights

  • Report
  • Europe
From
Semi-synthetic ß-lactam Antibiotics Market - Global Forecast 2026-2032 - Product Image

Semi-synthetic ß-lactam Antibiotics Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Beta Lactam & Beta Lactamase Inhibitors Market - Global Forecast 2026-2032 - Product Image

Beta Lactam & Beta Lactamase Inhibitors Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Beta Lactam and Beta Lactamase Inhibitors - Global Strategic Business Report - Product Image

Beta Lactam and Beta Lactamase Inhibitors - Global Strategic Business Report

  • Report
  • 391 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.